We investigated the early diagnostic utility, including incremental value, of the serum cardiac markers creatine kinase (CK), CK-MB (mass and activity measurements), cardiac troponin T, and myoglobin in the diagnosis of acute myocardial infarction (AMI) in patients presenting to a major teaching hospital with chest pain and non-diagnostic electrocardiographs (ECG). The reference diagnosis of acute myocardial infarction was made by a single, independent cardiologist using World Health Organization criteria. CK and CK-MB mass were the only significant predictors of AM1 at presentation to the Emergency Department. Logistic regression analysis revealed that C K did not significantly predict ( P = 0.23) myocardial infarction once CK-MB mass was in the model. Using test results on follow up, in addition to presentation CK-MB mass, change in CK-MB mass was the only other significant independent predictor of AMI. Likelihood ratios for various levels of the significant markers in the logistic regression are given. In conclusion, CK-MB mass measurement was the only useful serum cardiac marker for the diagnosis of AM1 in patients presenting with chest pain with non-diagnostic ECGs.
The diagnosis of acute myocardial infarction (AMI) can be missed in more than 50% of patients presenting with chest pain when only clinical history and electrocardiographic (ECG) changes are utilized.' An early diagnosis of AM1 is advantageous because the rapid assessment of chest pain and the early administration of thrombolytic therapy is beneficial in terms of morbidity and mortality and may reduce demand for hospital beds resulting in a significant cost saving.* The use of serum cardiac markers may have an important role in this early assessment. Recently, the use of mass measurements of the MB isoenzyme of creatine kinase Correspondence: Dr Ian A Katr. Medjsan Pathology, 200 The Boulevarde, Fairfield Heights 2165, NSW, Australia E-mail: kitkatz(a bigpond.com.au.
(CK, E.C. 2.7.3.2), the various CK isoforms, rapid serum myoglobin measurements and more cardiac-specific markers such as the troponins have all been reported to be of assistance in the early diagnosis of AMI.
The use of serum cardiac markers, however, remains problematic in terms of the practical application of the analytical and clinical specificity and sensitivity at various time points after the onset of chest pain. As is the case with many other diagnostic tests,5 the interpretation of the literature on serum cardiac markers is hampered by the generally poor quality of the study designs examining aspects of these markers. Studies of serum cardiac markers are often biased by the inclusion of patients with obvious ECG signs of AM1 in whom the measurement of any cardiac marker is essentially irrelevant for diagnosis. Additionally, the presentation of study results often does not allow the optimal application to individual patients. The incremental benefit of one test over another is another aspect that is not often examined when examining tests which are significant predictors of AM1 individually.6 Thus, in a prospective study, we investigated the test accuracy and incremental benefit of the biochemical markers, CK, CK-MB (activity and mass measurements), myoglobin and cardiac troponin T (cTnT) for the early ( < 1 2 h after the onset of pain) diagnosis of AM1 in patients without diagnostic electrocardiographic (ECG) changes.
PATIENTS AND METHODS

Patients
The study population consisted of 219 patients presenting to the Emergency Medicine Department of a large urban teaching hospital in Sydney, Australia within 12 h after the onset of chest pain. All eligible patients were enrolled, except: those with obviously identifiable noncardiac causes (e.g., chest trauma); uncertainty in the time of onset of the chest pain; pain for more than 12 h; and refusal of, or inability to obtain, consent. Eligible patients were identified by resident medical staff and consecutively enrolled. Enrolment in the study did not alter usual medical management. Permission for the study was granted by the Medical Research Ethics Committee of the Royal North Shore Hospital, and procedures followed were in accordance with their standards.
Samples
Blood samples for measurement of activities of CK, CK-MB, aspartate aminotransferase (AST; E.C. 2.6.1.1) and lactate dehydrogenase (LD; E.C. 1.1.1.27) and the mass concentrations of CK-MB, cTnT and myoglobin were taken on presentation to the emergency department and at 4, 8, and 12 h (n = 87, 150 and 159, respectively) after the onset of chest pain and then approximately daily for CK, CK-MB (by mass and activity), LD and AST for as long as the patients were hospitalized. Standard ECGs were performed on presentation and then routinely every 24 h or as required.
Diagnostic criteria
The probability of AM1 at presentation to the emergency department was made, retrospectively, by a cardiologist (GICN) using only symptoms, signs and the ECG on presentation and blinded to all other information in the clinical record. In accordance with the aims of the study, all patients whose presenting features suggested a probability of 1.0 of having an AM1 were eliminated from the 219 patients in the study population. The final reference diagnosis of AM1 was made retrospectively by the independent cardiologist using World Health Organization criteria including the clinical record, serial ECG changes, and the routinely used serum cardiac markers CK, CK-MB (mass or activity), AST and LD. To ensure complete independence of the test and reference standard, the cardiologist was blinded to the results for C K and CK-MB (mass and activity) during the initial 12 h after the onset of chest pain. The probability of AM1 was assessed on a scale of 0-1. All patients with a probability 30.5 of suffering an AM1 as determined by the reference diagnosis were regarded as having an AMI.
Analytical methods
Samples for cTnT and myoglobin were stored at -70°C until analysis. CK, AST and LD activity were measured at 37°C on a Hitachi 747 Analyser using manufacturer's methods (Boehringer Mannheim Australia Pty Ltd, Castle Hill, Sydney). The lower limits of detection, intraassay coefficient of variation and inter-assay coefficient of variation were 15 U/L, 0.4% and 2.5%; 2 U/L, 1.2% and 2.1%; and 2 U/L, 0.4% and 1.4%, respectively. CK-MB activity was measured by an immunoinhibition technique on the Hitachi 747 (lower limit of detection, intraassay coefficient of variation and inter-assay coefficient of variation were SU/L, 1.1% and 6.2O/0, respectively). Mass concentration of CK-MB (lower limit of detection, intra-assay coefficient of variation and inter-assay coefficient of variation were 0.7pg/L, 4.0% and 4.5%, respectively) was measured using a microparticle enzyme immunoassay technique on an Abbott ImX (Abbott Australia, North Ryde, Sydney). Cardiac TnT (lower limit of detection, intra-assay coefficient of variation and inter-assay coefficient of variation were 0.05 pg/L, 2.6% and 6%, respectively) was measured by an enzyme immunosorbent assay on a Boehringer Mannheim ES 300 while myoglobin (lower limit of detection and interassay coefficient of variation were 1 pg/L and 15.8%, respectively) was measured by an enzyme immunoassay on a Behring Opus immunoanalyser (Behring Diagnostics Australia Pty Ltd, Kingsgrove, Sydney).
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Statistical analysis
Statistical analysis was performed using SPIDA statistical software (Statistical Package for Interactive Data Analysis, Department of Statistics, Macquarie University, Sydney). Receiver operating characteristic (ROC) curves were generated using Microsoft Excel (Microsoft Corporation, North Ryde, Sydney). Samples at presentation were included in the 4, 8 or 12h ROC curve analyses if they were taken within 30 min of the appropriate time point, and if there was no specimen routinely collected at that time point. Change in serum cardiac markers was calculated by dividing the differences between consecutive results by the time difference in hours (which ranged from approximately 1 to 5 h). Logistic regression models were run initially on information available on presentation, starting with CK at presentation and testing whether the inclusion of additional serum markers added significantly to the prediction of AMI. Variables tested included all serum cardiac markers, and square terms of serum markers found to predict AM1 (to test for non-linearity of effect). The statistical significance of additional variables was tested by assessing the difference in deviance (which has a x2 distribution) between models that included or excluded that variable.
A similar method was followed for testing the effect of change in serum cardiac markers, except that the base model always included presentation results found to be important predictors, so that the incremental value of change in measurement could be assessed. Likelihood ratios were estimated from the logistic regression using the method described by Irwig.' Likelihood ratios can be defined as the ratio of the proportion of people with a given test result who have the target disorder to the proportion of people with that test result who do not have the target disorder.8
RESULTS
Patients
Two hundred and nineteen patients were enrolled in the study; one medical record was not available for analysis. Of the 218 classified: 90 were women and 128 were men; 55 (25%) were diagnosed as suffering an AM1 (retrospective reference diagnosis); 99 had unstable angina pectoris; three had angina pectoris; five had pericarditis; two had chest pain due to arrhythmias; and 54 had chest pain of undetermined origin (atypical chest pain). Twentythree patients were classified on history and ECG as having a probability of 1 .O of having an AM1 at presentation and were thus excluded from the statistical analysis, leaving 195 eligible for statistical analysis. Differences in the baseline characteristics between the remaining patients with and without AM1 are depicted in Table 1 .
Comparison of diagnostic performance
Single smmples ROC curves were generated for the results on samples at presentation as well as at each time point after the onset of chest pain, and areas under the ROC curves were compared. At *Not significantly different by t-test using unequal variances. ' P i 0.01. :<0.05. "his is the reference diagnosis. All patients with a probability >0,5 were considered to have had an AM1 AM1 =acute myocardial infarction; C K = creatine kinase; CK-MB = creatine kinase MB. presentation there were no important differences among any of the markers, except the ratio CK-MB (activity)/CK which provided no diagnostic information ( Table 2 ). The areas under ROC curves for the 4, 8 and 12h samples were 0.91, 0.92 and 0.89 for CK, 0.80, 0.86 and 0.85 for CK-MB (activity), 0.91, 0.89 and 0.89 for CK-MB (mass), 0.33, 0.33 and 0.42 for CK-MB(activity)/CK, 0.71, 0.82 and 0.83 for CK-MB(mass)/CK, 0.77,0.83 and 0.85 for cTnT and 0.85, 0.79 and 0.70 for myoglobin, respectively.
Analysis in the step-wise logistic regression was restricted to the 135 patients who had complete data sets for all analytes (of these 24 had AMI). Baseline CK was included in all stepwise logistic regression models as it was considered that these data would be available for all patients. The only serum marker that significantly added to CK at presentation in this patient population was CK-MB mass at presentation (Table 3) . Although both were predictive on their own, CK did not significantly improve the prediction of myocardial infarction once CK-MB mass was in the model (P=0.23). The addition of terms for non-linearity did not add significantly to the model. When all the other biochemical markers at presentation (CK-MB activity, CK-MB activity/CK percentage, CK-MB mass/CK index, myoglobin, or cTnT) were tested, none had any incremental predictive value. Likelihood ratios for CK-MB mass ranged from 0.02 for a CK-MB mass of 1 pg/L to 145 for a CK-MB mass of 30pg/L ( Table 4) .
Time-related changes7from presentation to next sample
When area under the ROC curves for changes per hour for the various analytes were compared the performance of change in CK, CK-MB activity and mass and cTnT were similar (see Table 2 ). Models for change of cardiac marker values included the presentation CK-MB mass as it was the only important independent predictor on presentation. Although both change in CK and change in CK-MB mass were predictors of myocardial infarction, only change in CK-MB mass remained significant in a model that included both variables in addition to the presentation CK-MB mass ( P value for change in CK 0.98) ( Table 5 ). The addition of terms for non-linearity and the elapsed time between presentation and repeat measurement were not statistically significant. None of the changes in other serum cardiac markers added significantly to the model, with the exception of cTnT. This added significantly (P<0.025) though in a negative direction, i.e. the higher the change in cTnT, the lower the risk of AMI, once CK-MB mass was known. However, cTnT is a significant positive predictor if CK-MB mass is not included in the equation. Likelihood ratios for various ranges of CK-MB mass at presentation and change are shown in Table 6 and demonstrate the incremental value of increasing rate of change with increasing baseline of CK-MB (mass). 
DISCUSSION
The aims of this study were to examine the role of the serum cardiac markers CK, CK-MB (mass and activity), cTnT and myoglobin in the early diagnosis of AM1 in patients presenting to the emergency department with chest pain and to produce likelihood ratios that could assist in the management of similar patient populations.
With the recognition that the early diagnosis of AM1 is useful in terms of early management and triage, there has been increasing debate recently about the clinical specificity and sensitivity of the serum cardiac markers compared to clinical parameters.' An established marker of AM1 is total CK but this has problems of cardiac non-specificity. Still, virtually all patients admitted to any hospital with chest pain have a serum CK measured. CK-MB assays have become arguably the most widely used confirmatory test for AMI,''," even though many early studies using the immunoinhibition methods did not seem to show significantly better diagnostic ability than total CK alone. l o The poor performance of the CK-MB assay was due to the high propensity for interference by CK-BB or CK-macroisoenzymes'* and may account for the poor performance of the CK-MB activity measurements (particularly as a ratio of CK) in the present study.
The immunoinhibition methods for measuring CK-MB activity are being replaced by quicker monoclonal antibody-based (usually immunometric) mass assays. Recent studies have investigated the application of these mass assays on single and serial samples in the diagnosis of AMI,I3,l4 and in patients with non-diagnostic ECGs have been shown to have greater accuracy for diagnosing AM1 than the ECG a10ne.l~ Similarly, but using logistic regression analysis, CK-MB mass on presentation was identified in the present study as the most significant predictor of AMI.
Neither of the other markers, cTnT or myoglobin, added to the predictive value of CK-MB mass. cTnT is highly cardiac-~pecific,'~ and has been shown to be useful in the medium to long-term diagnosis of AM1 and as an indicator of prognosis in unstable angina pectoris,16 but not in the early diagnosis of AM1 as confirmed in the present study. Specificity of cTnT (and also CK-MB mass) for the diagnosis of AM1 may be compromised by elevations in patients with unstable angina and so-called minimal myocardial damage. l 6 I* The finding that change in cTnT added significantly to the model but in a negative direction has no obvious biological explanation. It may be due to chance but requires further exploration if further reports in the literature confirm or deny this effect.
In the present study, in the ROC curve analysis, myoglobin appeared to perform as well as the other serum cardiac markers for the early diagnosis of AMI. However, in the logistic regression model myoglobin did not add significantly to CK activity and CK-MB mass measurements. Myglobin has been reported to be one of the earliest serum markers of AM1'y,20 but the lack of cardiac specificity of myoglobin contributed to its lack of predictive value in the present study.
Using ROC curve analysis, all the cardiac markers we examined were predictive of AM1 with the exception of CK-MB (activity)/CK. We used stepwise logistic regression analysis to determine which specific tests add incremental benefit over the other markers and found that CK-MB mass and change in CK-MB mass are the only independent predictors of AM1 in patients with non-diagnostic ECGs and clinical histories.
Likelihood ratios (LR) are simpler and more efficient to use than ROC curves in individual patients. Whatever the result of the CK-MB mass or change in CK-MB mass, the clinician still cannot be certain that AM1 is present. All the tests can do is modify the pre-test probability of AMI, yielding a post-test probability. The direction and magnitude of this change from pre-to post-test probability are determined by test properties of which the most important is the LR. The LR indicates how much the diagnostic test result lowers or raises the pretest probability and is in fact the slope of the ROC curve at any specified threshold.
For formal use, the pre-test probability is converted into an odds (probability/[l -probability]), multiplied by the LR, and finally reconverted (odds/([odds + I]) into a post-test probability. This method is cumbersome and therefore nomograms have been published to assist the clinician.2' For example, consider a patient who presents 2 h after the onset of chest pain and is assessed as having a 50% probability of having an AM1 on history, examination and first ECG. If the presentation CK-MB mass is lO.Opg/L and the CK-MB mass 6 h later is 18.0pg/L the change in CK-MB mass is 2 pg/L/h. Using presentation results only, the LR of CK-MB mass will be 0.26 (see Table 3 ). Using the nomogram, this gives a post-test probability of approximately 20%. Similarly, using the change in CK-MB mass value and Table 6 , a LR of approximately 0.4 can be estimated and this changes the post-test probability to only approximately 27%.
In patients presenting with chest pain, the pre-test probability of cardiac disease is dependent on many factors including history (age, risk factors, nature of pain, etc), examination and ECG criteria. A problem exists in the variable nature of the interpretation of these factors and transformation to an accurate probability by clinicians of various backgrounds and experience in the emergency department setting. To reduce error in the assessment of pre-test probability, the combined estimate of several clinicians can be used. Better still, a clinical algorithm such as that reported by Lee et ~1 .~ can be used.
In the current study among patients presenting to the emergency department within 12h after the onset of chest pain, with non-diagnostic clinical histories and ECGs, CK-MB mass and change in CK-MB mass were the main predictors of AMI. Once these test results were known, no other tests had incremental value, including CK which is universally measured in patients at presentation to the emergency department. The statistical approaches used in this paper can help to identify which tests are the most important predictors, and provide likelihood ratios for clinical decision-making.
